David T. Wong

5.0k citations

47 papers · 4.0k indexed · 3 hit papers · h-index 27

Cellular and Molecular Neuroscience top 1%
Molecular Biology top 5%
Psychiatry and Mental health top 1%
Pharmacology top 1%
Organic Chemistry top 5%

Co-authors: Frank P. Bymaster Eric A. Engleman Kenneth W. Perry Jong S. Horng David O. Calligaro Nicholas Moore Julie F. Falcone N.C. Tye
Topics: Neurotransmitter Receptor Influence on Behavior (16 papers)Treatment of Major Depression (12 papers)Receptor Mechanisms and Signaling (8 papers)
Cited by: Biological Psychiatry Cellular and Molecular Neuroscience Psychiatry and Mental health
Journals: Nature Science Nature Reviews Drug Discovery
Partner nations: United States United Kingdom Canada

In The Last Decade

David T. Wong

46 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

1996 855 citations Frank P. Bymaster, David O. Calligaro et al. Neuropsychopharmacology profile →
Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication

1995 552 citations David T. Wong, Frank P. Bymaster et al. Life Sciences profile →
A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine

1974 374 citations David T. Wong, Jong S. Horng et al. Life Sciences profile →

Peers

Countries citing papers authored by David T. Wong

Since Specialization

Citations

This map shows the geographic impact of David T. Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Wong more than expected).

Fields of papers citing papers by David T. Wong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Wong. The network helps show where David T. Wong may publish in the future.

Co-authorship network of co-authors of David T. Wong

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Wong. A scholar is included among the top collaborators of David T. Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Wong. David T. Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synthesis of 1,1-[1-Naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and Their Evaluation as Inhibitors of Serotonin, Norepinephrine, and Dopamine Transporters 2009 ·Journal of Medicinal Chemistry ·James D. White,(unknown),(unknown),(unknown),David T. Wong	9
2	Indoloxypropanolamine analogues as 5-HT1A receptor antagonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Joseph H. Krushinski,John M. Schaus,(unknown),David O. Calligaro,David L. Nelson,(unknown),David B. Wainscott,David T. Wong	10
3	The Discovery of Fluoxetine Hydrochloride (Prozac) 2005 ·Nature Reviews Drug Discovery ·David T. Wong,Kenneth W. Perry,Frank P. Bymaster	311
4	Advances toward new antidepressants beyond SSRIs: 1-Aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5 2005 ·Bioorganic & Medicinal Chemistry Letters ·Kumiko Takeuchi,Todd J. Kohn,(unknown),Vincent P. Rocco,(unknown),Susan K. Hemrick-Luecke,Linda Thompson,David C. Evans,Kurt Rasmussen,Deanna Koger,David Lodge,(unknown),Janice Shaw,Penny G. Threlkeld,David T. Wong	17
5	Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4 2004 ·Bioorganic & Medicinal Chemistry Letters ·Vincent P. Rocco,(unknown),Todd J. Kohn,(unknown),David L. Nelson,David B. Wainscott,(unknown),Janice Shaw,Penny G. Threlkeld,David T. Wong,Kumiko Takeuchi	30
6	Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 3 2003 ·Bioorganic & Medicinal Chemistry Letters ·Kumiko Takeuchi,Todd J. Kohn,(unknown),Vincent P. Rocco,(unknown),(unknown),Larry W. Hertel,David L. Nelson,David B. Wainscott,(unknown),Janice Shaw,Penny G. Threlkeld,David T. Wong	18
7	Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 1 2003 ·Bioorganic & Medicinal Chemistry Letters ·Kumiko Takeuchi,Todd J. Kohn,(unknown),Vincent P. Rocco,(unknown),Daniel J. Koch,David L. Nelson,David B. Wainscott,(unknown),Janice Shaw,Penny G. Threlkeld,David T. Wong	45
8	Advances Toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 2 2003 ·Bioorganic & Medicinal Chemistry Letters ·Kumiko Takeuchi,Todd J. Kohn,(unknown),Vincent P. Rocco,(unknown),Daniel J. Koch,(unknown),Larry W. Hertel,David L. Nelson,David B. Wainscott,(unknown),Janice Shaw,Penny G. Threlkeld,David T. Wong	20
9	Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake 2003 ·Bioorganic & Medicinal Chemistry Letters ·F.P. Bymaster,(unknown),Jeremy Findlay,P. T. Gallagher,Joseph H. Krushinski,S.N. Mitchell,David W. Robertson,David C. Thompson,Louise Wallace,David T. Wong	93
10	Dual serotonin and noradrenaline uptake inhibitor class of antidepressants — Potential for greater efficacy or just hype? 2002 ·Birkhäuser Basel eBooks ·David T. Wong,Frank P. Bymaster	92
11	Olanzapine increases extracellular dopamine release and blocks dopamine, serotonin and muscarinic receptors in vivo 1997 ·Schizophrenia Research ·Frank P. Bymaster,Ximing Li,(unknown),David T. Wong,Kenneth W. Perry	2
12	Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapinebreakdown → 1996 ·Neuropsychopharmacology ·Frank P. Bymaster,David O. Calligaro,Julie F. Falcone,(unknown),Nicholas Moore,N.C. Tye,Philip Seeman,David T. Wong	855
13	Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationbreakdown → 1995 ·Life Sciences ·David T. Wong,Frank P. Bymaster,Eric A. Engleman	552
14	3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity 1993 ·Journal of Medicinal Chemistry ·Charles H. Mitch,J. David Leander,Laurane G. Mendelsohn,Walter N. Shaw,David T. Wong,Buddy E. Cantrell,Bryan G. Johnson,(unknown),(unknown)	50
15	LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake 1993 ·Neuropsychopharmacology ·David T. Wong,Frank P. Bymaster,(unknown),Leroy R. Reid,Joseph H. Krushinski,David W. Robertson	187
16	Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity 1989 ·Journal of Medicinal Chemistry ·Loretta A. McQuaid,(unknown),James A. Clemens,R W Fuller,David T. Wong,Norman R. Mason	14
17	Synthesis and pharmacology of a series of 3- and 4-(phosphonoalkyl)pyridine- and -piperidine-2-carboxylic acids. Potent N-methyl-D-aspartate receptor antagonists 1989 ·Journal of Medicinal Chemistry ·Paul L. Ornstein,John M. Schaus,John Whiteclay Chambers,(unknown),J. David Leander,David T. Wong,Jonathan W. Paschal,Noel D. Jones,Jack B. Deeter	49
18	Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor 1988 ·Journal of Medicinal Chemistry ·David W. Robertson,Noel D. Jones,J. K. SWARTZENDRUBER,(unknown),David T. Wong	70
19	A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. 1982 ·Journal of Pharmacology and Experimental Therapeutics ·David T. Wong,Penny G. Threlkeld,Kevin L. Best,F.P. Bymaster	160
20	Pharmacologic Effects in Man of a Specific Serotonin-Reuptake Inhibitor 1978 ·Science ·Louis Lemberger,Howard Rowe,(unknown),(unknown),Jong S. Horng,Frank P. Bymaster,David T. Wong	36

About David T. Wong

David T. Wong is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Organic Chemistry, having authored 47 papers that have together received 4.0k indexed citations. Recurring topics across this work include Neurotransmitter Receptor Influence on Behavior (16 papers), Treatment of Major Depression (12 papers) and Receptor Mechanisms and Signaling (8 papers). The work is most often cited by research in Biological Psychiatry (277 citations), Cellular and Molecular Neuroscience (1.7k citations) and Psychiatry and Mental health (819 citations). David T. Wong has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Frank P. Bymaster, Frank P. Bymaster, Eric A. Engleman, Kenneth W. Perry, Jong S. Horng, David O. Calligaro, Nicholas Moore, Julie F. Falcone, N.C. Tye and Philip Seeman. Their work appears in journals such as Nature, Science and Nature Reviews Drug Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact